Healthcare
The Inflation Reduction Act, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives.
With more than 6,600 cases of monkeypox in the United States, the Biden administration declared the viral outbreak a public health emergency as cases continue to rise across the nation.
Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).
Dr. Amaka Eneanya told BioSpace that kidney disease, which disproportionately affects people of color, has historically been underrepresented in clinical research compared to other areas of medicine.
As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.
Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
Although no new safety concerns were observed, Merck’s Keytruda did not demonstrate significant improvements based on the pre-specified statistical plan.
BioSpace sat down with Katy Powell, a psychiatric mental health nurse practitioner in Portland, Oregon, to discuss the relative risks and benefits associated with psychedelic-assisted therapy.
GSK launched the “Target the Future” initiative to improve the care of patients diagnosed with multiple myeloma, the third most common form of hematological cancer.
BD, a leading global medical technology company, has expanded its BD MAX System platform to include a polymerase chain reaction (PCR) test for monkeypox.
PRESS RELEASES
